<DOC>
	<DOCNO>NCT02801370</DOCNO>
	<brief_summary>This prospective , randomize , double-blind , sham-controlled , multicenter , Phase 3 study eligible subject acute otitis externa ( AOE ) randomize receive single administration either 12 mg OTO-201 Sham-Control ( empty syringe ) external auditory canal affect ear ( ) .</brief_summary>
	<brief_title>Phase 3 Study OTO-201 Acute Otitis Externa</brief_title>
	<detailed_description />
	<mesh_term>Otitis</mesh_term>
	<mesh_term>Otitis Externa</mesh_term>
	<mesh_term>Ciprofloxacin</mesh_term>
	<criteria>Inclusion Criteria include , limited : Subject male female age 6 month old Subject clinical diagnosis unilateral bilateral acute otitis externa Subject subject 's caregiver willing comply protocol attend study visit Exclusion Criteria include , limited : Subject tympanic membrane perforation Subject eczematoid otitis externa Subject diabetes mellitus</criteria>
	<gender>All</gender>
	<minimum_age>6 Months</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>